


What the FDA Actually Cleared When UpDoc Became the First Patient-Facing LLM Medical Device: A Stanford Insulin-Titration Trial, a Drug-Dose-Calculator Predicate, and the Real Shape of Clinical AI

JUN 29, 2026 • PAID



Video Preview

Could not load video.

 **Podcast episode for paid subscriber only. Also available on Spotify.**



Thoughts on Healthcare Markets & Technology

 **What the FDA Actually Cleared When UpDoc Became the First Patient-Facing LLM Medical Device: A Stanford Insulin-Titration Trial, a Drug-Dose-Calculator Predicate, and the Real Shape of Clinical AI**

The FDA just cleared the first patient-facing LLM medical device. The headline says it redefined clinical AI. The actual clearance file tells a more interesting story...

▶ Listen now

4 hours ago · Thoughts on Healthcare

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

UpDoc, a Palo Alto company spun out of Stanford in 2023, announced on June 2026 what it called the first FDA-cleared clinical AI platform with a patient-facing LLM, alongside \$18M in seed funding and deployments at four major health systems. Strip away the press release and the actual regulatory artifact is narrower and far more interesting: a 510(k) (K253281, cleared Dec 23, 2025) for a prescription SaaS that manages basal insulin in adults with type 2 diabetes, cleared as substantially equivalent to a drug-dose calculator (Hygieia d-Nav, K181916), under product code NDC, regulation 21 CFR 868.1890. The clinical evidence base traces to a 32-patient randomized trial (MIVA, NCT05081011) published in JAMA Network Open. This piece walks the gap between the category-defining narrative and the bounded device that actually got cleared, why the boring regulatory path was the smart one, who funded it (Lilly, Mayo, the ADA, Section 32, Polaris, Pear, Cathay, Oxeon), and what the precedent does and does not unlock for everyone trying to build the next one.

Quick hits:

1. FDA cleared a calculator that can talk, not an autonomous doctor.
2. The LLM sits outside a deterministic dosing core.
3. No clinical testing was required for the clearance.
4. A PCCP was authorized, with limits.
5. The strategic cap table tells you who thinks this category is real.

Table of Contents

Two stories, one company

It started with thirty-two patients and a voice bot

Read the clearance, not the headline

A chatbot bolted onto a calculator

Why the boring regulatory path was the smart one

Who wrote the checks and what they bought

What the rest of the field should take from this

Thoughts on Healthcare Markets &
Technology is a reader-supported
publication. To receive new posts and
support my work, consider becoming a
free or paid subscriber.

Two stories, one company

There are two versions of UpDoc circulating right now, and they do not really seem like the same product. The first version is the one that hit the wire this past June, one with the phrase clinical AI in bold energy, defined as artificial intelligence that delivers care historically requiring a licensed clinician. In that telling, UpDoc appears as the company that did the hard thing responsibly while everyone else raced to throw the word doctor on a chatbot, and the FDA blessing is the proof. Andy Conrad, former Verily chief and Section 32 partner, supplied the canonical quote about UpDoc not just redefining the category but establishing what it means to do it responsibly. The CEO, Sharif Vakili, supplied the line about clinical AI being held to the highest standard. The whole thing reads like the opening of a new chapter in medicine.

The second version is the one sitting in the FDA's public database, and it is a good deal more modest. That version is a prescription software device that helps adults

with type 2 diabetes titrate their basal insulin, cleared because it is substantially equivalent to a dosing calculator that has existed for years. Both versions are true at the same time, which is the part worth sitting with. The interesting thing about UpDoc is not that the marketing oversells it, because all health tech marketing oversells. The interesting thing is the specific, deliberate engineering of the gap between what was built and what was claimed, and how cleverly the regulatory strategy threaded a needle that a lot of better-funded companies have face-planted. For an audience that has watched a decade of digital health companies confuse a release with a business, the UpDoc clearance is less a milestone and more a case study in how to get a large language model across the FDA finish line without pretending it does something it does not.



Continue reading this post for free, courtesy of Thoughts on Healthcare.

[Claim my free post](#)

[Or purchase a paid subscription.](#)

[← Previous](#)